ClinicalTrials.gg
RecruitingNCT05937191Lef for IPHUpdated Jul 10, 2023

Leflunomide for Idiopathic Pulmonary Hemosiderosis in Children

A Phase 1/2 interventional study of Leflunomide and Steroid Drug in Idiopathic Pulmonary Hemosiderosis and Leflunomide, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Recruiting at 1 site in China. Open to participants aged 5 Months to 18 Years. Per ClinicalTrials.gov, last updated 2023-07-10.

Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
5 Months to 18 Years
Sex
All
01

Study summary

The goal of this clinical trial is to compare Leflunomide in Idiopathic pulmonary hemosiderosis. The main questions it aims to answer are:

  • The efficacy and safety of Leflunomide in Idiopathic pulmonary hemosiderosis
  • The mechanism of leflunomide in treating Idiopathic pulmonary hemosiderosis Participants will be treated with leflunomide plus stroid. A comparison group: Researchers will compare the control group treated with stroid to see if the efficacy of Leflunomide would be better than control group.
Read the detailed description

This study conducted a prospective, open, parallel controlled, single center clinical trial on the combination of Leflunomide and Stroid therapy for children with IPH, and conducted a one-year follow-up. The main indicators (pulmonary hemorrhage/hemoptysis frequency) and secondary indicators (serum iron metabolism level, T lymphocyte subpopulation, lung function, inflammatory cells, and inflammatory factors) were evaluated before and after treatment, Exploring the safety and effectiveness of leflunomide in the treatment of IPH, it is expected that the combination of leflunomide and conventional treatment can improve the remission rate of clinical symptoms in children with IPH, inhibit the progressive deterioration of lung function, and the research results are expected to bring new treatment methods and strategies for this group of patients.

02

Conditions studied

  • Idiopathic Pulmonary Hemosiderosis
  • Leflunomide

Keywords

  • Idiopathic pulmonary hemosiderosis
  • Leflunomide
  • glucocorticoid
03

In context

Lead sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University is the lead sponsor of 484 studies on the registry; 284 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Months to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age range from 6 months to 18 years old;
  2. Diagnose as IPH;
  3. Parents or guardians agree to treatment and sign a written form.

Exclusion criteria

Exclusion Criteria:

  1. Individuals who are allergic to any ingredients used in leflunomide tablets;
  2. Complicated with serious basic diseases (such as systemic malignant diseases, heart failure, liver and kidney failure, immune deficiency, serious infectious diseases, Lung transplantation or other patients with immediate surgical indications);
  3. Patients with other lung diseases;
  4. Have a history of abnormal coagulation or abnormal coagulation function in the past;
  5. Clinical trial participants who have previously participated in the treatment of flumiphene;
  6. Other situations where the researcher deems it inappropriate to participate in the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    IPH Patients

    Leflunomide+Steroid treatment

    Drug: Leflunomide

  • Active comparator
    Control Group

    Steroid treatment

    Drug: Steroid Drug

Interventions

06

What researchers measure

Primary outcomes

  1. Times of pulmonary hemorrhage

    Annual times of acute episodes of pulmonary hemorrhage

    Time frame: 12 months

Secondary outcomes

  1. Rate of adverse reaction

    The frequency of adverse reactions and their relationship with leflunomide

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2023 (actual). Primary completion is estimated for Dec 2026, 42 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2023
First posted
Jul 10, 2023
StartActual
Jun 1, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05937191
Responsible party
Weiping Tan (Professor, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University) — Principal investigator
First posted
Jul 10, 2023
Start date
Jun 1, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 10, 2023

Study contacts

Haiyan Wang, MD
Contact
wanghy78@mail.sysu.edu.cn
8613560489257
Weiping Tan, PhD
Contact
tanweip@mail.sysu.edu.cn
8613556196566

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leflunomide

Start the discussion